![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0011.png)
Page 31
conferenceseries
.com
Volume 7, Issue 5 (Suppl)
J Clin Exp Pathol
ISSN: 2161-0681 JCEP, an open access journal
Pathology Congress 2017
November 13-14, 2017
NOVEMBER 13-14, 2017 OSAKA, JAPAN
14
th
Asia Pacific Pathology Congress
Interpretation of hormone receptors, Her2/neu and Ki-67 in mammary carcinoma
Ahmed M Abdelaziz Amer
Cairo University, Egypt
I
mmunohistochemistry (IHC) combines anatomic, immunologic and biochemical techniques to identify specific tissue
components using a specific antigen-antibody reaction labeledwith a visible reporter molecule.This binding is then visualized
through the use of various enzymes that are coupled to the antibodies being used. The enzyme acts on a chromogenic substrate
to cause deposition of a colored material at the site of antibody-antigen bindings. IHC is not only critical for the accurate
diagnosis of malignancies but also plays a pivotal role in prognostic evaluation (e.g., estrogen and progesterone receptors in
breast cancer) and treatments strategies (e.g., Her2/neu in certain breast cancers). It is recommended that hormone receptor
and Her2/neu testing be done on all primary invasive breast carcinomas and on recurrent or metastatic tumors. If hormone
receptors and Her2/neu are both negative on a core biopsy, repeat testing on a subsequent specimen should be considered,
particularly when the results are discordant with the histo-pathologic findings. Other biomarker tests (e.g., Ki-67 or multi-gene
expression assays) are optional and are not currently recommended for all carcinomas. Guidelines published by the American
Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) require recording specific pre-analytic
and analytic variables that can affect test results. Information regarding assay validation or verification should be available
in the laboratory. Any deviation(s) from the laboratory’s validated methods should be recorded. Appropriate positive and
negative controls should be used and evaluated.
Biography
Ahmed MAbdelaziz Amer is a Professor and Head of Pathology Department, Faculty of Medicine, Cairo University in Egypt. He has completed his MD in Pathology
in 1991. He has graduated from Medical School of Cairo University in 1982. He has joined Department of Pathology, completed his Pathology training and received
MSc degree in Pathology in 1987. He is a Consultant and Head of Pathology Unit in Almokhtabar Lab.
aahmed85@hotmail.comAhmed M Abdelaziz Amer, J Clin Exp Pathol 2017, 7:5 (Suppl)
DOI: 10.4172/2161-0681-C1-040